

## Henrik Gregersen – Publication list

Gimsing P, Holmström MO, Klausen TW, Andersen NF, Gregersen H, Pedersen RS, Plesner T, Pedersen PT, Frederiksen M, Frølund U, Helleberg C, Vangsted A, de Nully Brown P, Abildgaard N. The Danish National Multiple Myeloma Registry. *Clinical Epidemiology* 2016; 8:583-587.

Sorrig R, Klausen TW, Salomo M, Vangsted AJ, Ostergaard B, Gregersen H, Frolund UC, Andersen NF, Helleberg C, Andersen KT, Pedersen RS, Pedersen P, Abildgaard N, Gimsing P. Smoldering multiple myeloma risk factors for progression: a Danish population-based cohort study. *Eur J Haematol* 2016; 97:303-309.

Gimsing P, Hjertner Ø, Abildgaard N, Andersen NF, Dahl TG, Gregersen H, Klausen TW, Mellqvist U-H, Linder O, Lindås R, Clausen NF, Lenhoff S. Salvage bortezomib-dexamethason and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase2 trial. *Bone Marrow Transplantation* 2015; 50:1306-1311.

Holmström MO, Gimsing P, Abildgaard N, Andersen NF, Helleberg C, Clausen NA, Klausen TW, Frederiksen M, Kristensen DL, Larsen H, Pedersen PT, Andersen KT, Pedersen RS, Jensen BA, Gregersen H, Vangsted AJ. Causes of early death in multiple myeloma patients who are ineligible for high-dose therapy with hematopoietic stem cell support: A study based on the nationwide Danish Myeloma Database. *Am J Hematol* 2015; 90: E73-4.

Andersen NF, Vogel U, Klausen TW, Gimsing P, Gregersen H, Abildgaard N, Vangsted AJ. Polymorphisms in the heparanase (HSPE) gene in multiple myeloma - association with bone morbidity and survival. *Eur J Haematol* 2015; 94:60-66.

Vangsted AJ, Klausen TW, Gimsing P, Abildgaard N, Andersen NF, Gang AO, Holmström M, Gregersen H, Vogel U, Schwarz P, Jørgensen NR. Genetic variants in the P2RX7 gene are associated with risk of multiple myeloma. *Eur J Haematol* 2014; 93: 172-174.

van de Donk N, Palumbo A, Johnsen HE, Engelhardt M, Gay F, Gregersen H, Hajek R, Kleber M, Ludwig H, Morgan G, Musto P, Plesner T, Sezer O, Terpos E, Waage A, Zweegman S, Einsele H, Sonneveld P, Lokhorst HM on behalf of the European Myeloma Network. The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network. *Haematologica* 2014; 99: 984-996.

Mellqvist UH, Gimsing P, Hjertner O, Lenhoff S, Laane E, Remes KJ, Steingrimsdottir H, Abildgaard N, Ahlberg L, Blimark CH, Skeibrok IM, Dahl IM, Forsberg K, Gedde-Dahl T, Gregersen H, Gruber A,

Gulbrandsen N, Haukas E, Carlson KE, Kvam AK, Nahi H, Lindas R, Andersen NF, Turesson I, Waage A, Westin J. Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma; a Nordic Myeloma Study Group randomized phase III trial. *Blood* 2013; 121: 4647-54.

Gregersen H, Brenner Larsen CE, Haglund A, Mortensen R, Andersen NF, Nørgaard M. Data quality of the Monoclonal Gammopathy of Undetermined Significance (MGUS) diagnosis in a Hospital Registry. *Clinical Epidemiology* 2013; 27: 321-6.

Møller HJ, Pedersen L, Bjerregaard MP, Jørgensen MK, Gregersen H. Analyse for M-komponent - Sådan gør vi i Danmark. *Klinisk Biokemi i Norden* 2013; 25: 26-29.

Andersen NF, Vogel U, Klausen TW, Gimsing P, Gregersen H, Abildgaard N, Vangsted AJ. Vascular endothelial growth factor (VEGF) gene polymorphisms may influence the efficacy of thalidomide in multiple myeloma. *Int J Cancer* 2012; 131: E636-42.

Vangsted AJ, Klausen TW, Abildgaard N, Andersen NF, Gimsing P, Gregersen H, Nexø BA, Vogel U. Single nucleotide polymorphisms in the promoter region of the IL1B gene influence outcome in multiple myeloma patients treated with high-dose chemotherapy independently of relapse treatment with thalidomide and bortezomib. *Ann Hematol* 2011; 90: 1173-81.

Gregersen H, Nørgaard M, Severinsen MT, Engebjerg MC, Jensen P, Sørensen HT. Monoclonal gammopathy of undetermined significance and risk of venous thromboembolism. *Eur J Haematol* 2011; 86: 129-134.

El-Galaly TC, Gregersen H, Bukh A. Goods syndrom med både lymfopeni og neutropeni. *Ugeskrift for Læger* 2011; 173: 280-281.

Vangsted AJ, Klausen TW, Gimsing P, Abildgaard N, Andersen NF, Gregersen H, Nexø BA, Vogel U. The importance of a sub-region on chromosome 19q13.3 for prognosis of multiple myeloma patients after high-dose treatment and stem cells support: A linkage disequilibrium mapping in RAI and CD3EAP. *Ann Hematol* 2011; 90:675-684.

Teodorescu M, Engebjerg MC, Johansen P, Nørgaard M, Gregersen H. Incidence, risk of infection and survival of hairy cell leukaemia in Denmark. *Dan Med Bull* 2010; 57: A4216.

Gimsing P, Carlson K, Turesson I, Fayers P, Waage A, Vangsted A, Mylin A, Gluud C, Juliusson G, Gregersen H, Hjorth-Hansen H, Nesthus I, Dahl IM, Westin J, Nielsen JL, Knudsen LM, Ahlberg L, Hjorth M, Abildgaard

N, Andersen NF, Linder O, Wisløff F. Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial. *Lancet Oncol* 2010; 11: 973-982.

Gregersen H, Sørensen HT, Engebjerg MC, Jensen P, Severinsen MT, Nørgaard M. Survival of cancer patients with prior monoclonal gammopathy of undetermined significance. *Eur J Intern Med* 2010; 21; 564-568.

Vangsted AJ, Soeby K, Klausen TW, Abildgaard N, Andersen NF, Gimsing P, Gregersen H, Vogel U, Werge T, Rasmussen HB. No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with multiple myeloma. *BMC Cancer* 2010; 10; 404.

Vangsted AJ, Klausen TW, Andersen NF, Abildgaard N, Gang AO, Gregersen H, Vogel U, Gimsing P. Improved survival of multiple myeloma patients with late relapse after high-dose treatment and stem cell support; A population-based study of 348 patients in Denmark in 1994-2004. *European Journal of Haematology*, 2010; 85:209-216.

Vangsted AJ, Klausen TW, Gimsing P, Andersen NF, Abildgaard N, Gregersen H, Vogel U. A polymorphism in NFKB1 is associated with improved effect of interferon- maintenance treatment of patients with multiple myeloma after high-dose treatment with stem cell support. *Haematologica* 2009; 94: 1274-1281.

Bird J, Behrens J, Westin J, Turesson I, Drayson M, Beetham R, D'Sa S, Soutar R, Waage A, Gulbrandsen N, Gregersen H, Low E. UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS). *Br J Haematol* 2009; 147: 22-42.

Vangsted AJ, Klausen TW, Ruminski W, Gimsing P, Andersen NF, Gang AO, Abildgaard N, Knudsen LM, Nielsen JL, Gregersen H, Vogel U. The polymorphism IL-1beta T-31C is associated with a longer overall survival in patients with multiple myeloma undergoing auto-SCT. *Bone Marrow Transplant* 2009; 43: 539-45.

Lund T, Gregersen H, Vangsted A, Marker P, Abildgaard N. Bisfosfonatassocieret osteonekrose i kæberne hos patienter med myelomatose. *Ugeskrift for Læger* 2009; 171; 50-52.

Schrøder H, Kjeldahl M, Boesen AM, Nielsen OJ, Schmidt K, Johnsen HE, Gregersen H and Gustafsson G. Akut lymfoblastær leukæmi (ALL) hos børn og unge mellem 10 og 20 år i Danmark. *Ugeskrift for Læger* 2006; 168: 2554-2558.

Gregersen H, Jensen P, Gislum M, Jørgensen B, Sørensen HT, Nørgaard M. Fracture risk in patients with monoclonal gammopathy of undetermined significance. *Br J Haematol* 2006; 135: 62-67.

Bertelsen J, Severinsen MT, Gregersen H. Dyb venøs trombose udløst af alvorlig infektion med hæmolytiske streptokokker gruppe A. *Ugeskrift for læger* 2006; 168: 2260-2261.

Nørgård M, Poulsen AH, Pedersen L, Gregersen H, Friis S, Ewertz M, Johnsen HE, Sørensen HT. Use of postmenopausal hormone replacement therapy and risk of non-Hodgkin's lymphoma: a Danish Population-based Cohort Study. *Br J Cancer* 2006; 94: 1339-1341.

Smedby KE, Hjalgrim H, Askling J, Chang ET, Gregersen H, et al. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. *J Natl Cancer Inst* 2006; 98: 51-60.

Neumann B, Gregersen H. Bisfosfonat og knoglenekroser i kæberne hos to myelomatosepatienter. *Ugeskrift for læger* 2006; 168: 2078-2079.

Neumann B, Gregersen H. Bisphosphonat-induceret knoglenekroser i kæberne. *Tandlægebladet* 2005; 109: 718-721.

Nørgaard M, Skriver MV, Gregersen H, Pedersen G, Schønheyder HC, Sørensen HT. The data quality of haematological malignancy ICD-10 diagnoses in a population-based Hospital Discharge Registry. *Eur J Cancer Prev* 2005; 14: 201-6.

Gregersen H, Pedersen G, Svendsen N, Thulstrup AM, Sørensen HT, Schønheyder HC. Multiple myeloma following an episode of community-acquired pneumococcal bacteraemia or meningitis. *APMIS* 2001; 109: 797-800.

Gregersen H, Mellekjær L, Ibsen JS, Dahlerup JF, Thomassen L, Sørensen HT. The impact of M-component type and immunoglobulin concentration on the risk of malignant transformation in patients with monoclonal gammopathy of undetermined significance. *Haematologica* 2001; 86: 1172-1179.

Gregersen H, Ibsen JS, Mellekjær L, Dahlerup JF, Olsen JH, Sørensen HT. Mortality and causes of death in patients with monoclonal gammopathy of undetermined significance. *Br J Haematol* 2001; 112: 353-357.

Gregersen H, Mellemkjær L, Ibsen JS, Sørensen HT, Olsen JH, Pedersen JO, Dahlerup JF. Cancer risk in patients with monoclonal gammopathy of undetermined significance. *Am J Hematol* 2000; 63; 1-6.

Andersen BS, Olsen J, Nielsen GL, Steffensen FH, Sørensen HT, Bæch J, Gregersen H. Third generation oral contraceptives and heritable thrombophilia as risk factors of non-fatal venous thromboembolism. *Tromb Haemost* 1998; 79: 28-31.

Gregersen H, Madsen KM, Sørensen HT, Schönheyder HC, Ibsen JS, Dahlerup JF. The risk of bacteremia in patients with monoclonal gammopathy of undetermined significance. *Eur J Haematol* 1998; 61; 140-144.